Price movement over the last 24 hours
AdaptHealth Corp vs Humana Inc — how do they compare? AdaptHealth Corp trades at $10.05 (market cap $1.38B), while Humana Inc trades at $401.51 (market cap $47.38B). The key difference: Humana Inc is far larger — about 34.3× AdaptHealth Corp's market cap, and Humana Inc pays a 0.9% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | HUM | |
|---|---|---|
Market Cap | $1.38B | $47.38B |
Sector | Health | Health |
52-Week High | $13.38 | $409.42 |
52-Week Low | $8.68 | $163.67 |
Enterprise Value | $3.33B | $56.42B |
Dividend Yield | — | 0.9% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
Humana (HUM) trades at $394.62, down 0.54% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. Revenue growth is strong, reaching $129.66B in 2025, though net income margin has compressed to 0.82%. Recent news highlights expansion through Medicaid contracts and divestitures, alongside legal scrutiny over healthcare costs. The stock shows resilience with consistent earnings beats but faces profitability pressures.
Outlook is mixed: bullish technicals and revenue growth support upside, but margin erosion and legal risks pose challenges. Analysts are cautious with a consensus hold rating and price target of $315, below the current price. Investors should weigh solid fundamentals against regulatory and competitive headwinds for balanced risk-reward assessment.
Trailing returns across standard periods
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →